rss

This article has a correction

Please see: Gut 2004;53:774

Gut 52:363-369 doi:10.1136/gut.52.3.363
  • Inflammatory bowel disease

Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

  1. J O Lindsay1,
  2. C J Ciesielski1,
  3. T Scheinin2,
  4. F M Brennan1,
  5. H J Hodgson3
  1. 1Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, London, UK
  2. 2Fourth Department of Surgery, University of Helsinki Central Hospital, Kasarmikatu 11-13, FIN-00130 Helsinki, Finland
  3. 3Department of Hepatology, Royal Free and University College Medical School, Royal Free Campus, London, UK
  1. Correspondence to:
    Dr J O Lindsay, Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, London W6 8LH, UK;
    j.lindsay{at}doctors.org.uk
  • Accepted 18 September 2002

Abstract

Introduction: Interleukin 10 knockout (IL-10−/−) mice spontaneously develop a Th1 T cell mediated colitis with many similarities to Crohn’s disease. Daily injections of IL-10 are unable to induce remission in mice with established disease. In contrast, we have shown previously that intravenous administration of adenoviral vectors encoding IL-10 (AdvmuIL-10) induces hepatic IL-10 release and leads to long term disease suppression with profound systemic immunoregulatory changes.

Aims: To determine whether rectal delivery of AdvmuIL-10 induces localised colonic IL-10 expression without systemic immune suppression, and assess its therapeutic efficacy in IL-10−/− mice with established colitis.

Results: A single rectal infusion of 5×108 PFU AdvmuIL-10 to 10 week IL-10−/− mice resulted in a median level of 27.3 pg/mg IL-10 in colonic homogenates harvested one week later. IL-10−/− mice with established colitis treated with an enema of 5×108 PFU AdvmuIL-10 entered clinical and histological remission whereas empty cassette adenovirus (Adv0) or phosphate buffered saline (PBS) treated mice developed progressive disease. After four weeks, the histological score of AdvmuIL-10 treated mice (4.4 (1.5)) was significantly lower than that of Adv0 (11.1 (1.1); p<0.001) and PBS (10.9 (1.0); p<0.01) treated controls. In addition, the stool concentration of IL-1β over the four week experiment was significantly higher in mice treated with saline or Adv0 than in those treated with AdvmuIL-10 (p<0.01).

Conclusion: Local AdvmuIL-10 therapy reverses colitis in IL-10−/− mice without the systemic effects seen after intravenous administration. Gene therapy strategies using adenoviral vectors encoding immunoregulatory cytokines may prove to be a potent approach to the treatment of chronic inflammatory diseases such as Crohn’s disease.

Footnotes